Genetically engineered T cells to target EGFRvIII expressing glioblastoma

Journal of Neuro-Oncology

Volumn 94, Issue 3, 2009, Pages 373-382

  Bullain, Szofia S ^a   Sahin, Ayguen ^a   Szentirmai, Oszkar ^a   Sanchez, Carlos ^a   Lin, Ning ^a   Baratta, Elizabeth ^a   Waterman, Peter ^a   Weissleder, Ralph ^a   Mulligan, Richard C ^b   Carter, Bob S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adoptive immunotherapy; Chimeric immune receptor; Chimeric T cell receptor; EGFRvIII; Glioma; MR1

Indexed keywords

CHIMERIC PROTEIN; CHIMERIC T LYMPHOCYTE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GAMMA INTERFERON; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL EXPANSION; CELL KILLING; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG TARGETING; FEMALE; GENE EXPRESSION; GENE TARGETING; GENETIC ENGINEERING; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO SELECTION; IN VIVO STUDY; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR XENOGRAFT;

ANALYSIS OF VARIANCE; CANCER VACCINES; CELL LINE, TUMOR; CELLS, CULTURED; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; GENE EXPRESSION; GLIOBLASTOMA; GREEN FLUORESCENT PROTEINS; HUMANS; LEUKOCYTES, MONONUCLEAR; RECEPTOR, EPIDERMAL GROWTH FACTOR; T-LYMPHOCYTES; TRANSFECTION;

EID: 69249248185     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-9889-1     Document Type: Article

References (30)

1. Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP et al (2007) Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 25(16):2288-2294. doi: 10.1200/JCO.2006.08.0705
2. Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH et al (2003) Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 9(11):4247-4254
3. Ochiai H, Archer GE, Herndon JEII, Kuan CT, Mitchell DA, Bigner DD et al (2008) EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8 + T cells. Cancer Immunol Immunother 57(1):115-121. doi: 10.1007/s00262-007-0363-7
4. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM et al (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314(5796):126-129. doi: 10.1126/ science.1129003
5. Sadelain M, Riviere I, Brentjens R (2003) Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 3(1):35-45. doi: 10.1038/nrc971
6. Facoetti A, Nano R, Zelini P, Morbini P, Benericetti E, Ceroni M et al (2005) Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin Cancer Res 11(23):8304-8311. doi: 10.1158/1078-0432.CCR-04-2588
7. Becker ML, Near R, Mudgett-Hunter M, Margolies MN, Kubo RT, Kaye J et al (1989) Expression of a hybrid immunoglobulin-T cell receptor protein in transgenic mice. Cell 58(5):911-921. doi: 10.1016/0092-8674(89)90943-4
8. Kawasaki H, Becker ML, Hedrick SM (1991) Specificity for molecules of the major histocompatibility complex mediated by a hybrid immunoglobulin-T cell receptor. New Biol 3(5):487-497
9. Roberts MR, Qin L, Zhang D, Smith DH, Tran AC, Dull TJ et al (1994) Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood 84(9):2878-2889
10. Gross G, Waks T, Eshhar Z (1989) Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 86(24):10024-10028. doi: 10.1073/ pnas.86.24.10024
11. Lorimer IA, Keppler-Hafkemeyer A, Beers RA, Pegram CN, Bigner DD, Pastan I (1996) Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: Targeting with a single chain antibody variable domain isolated by phage display. Proc Natl Acad Sci USA 93(25):14815-14820. doi: 10.1073/pnas.93.25.14815
12. Beers R, Chowdhury P, Bigner D, Pastan I (2000) Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display. Clin Cancer Res 6(7):2835-2843
13. Niederman TM, Ghogawala Z, Carter BS, Tompkins HS, Russell MM, Mulligan RC (2002) Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc Natl Acad Sci USA 99(10):7009-7014. doi: 10.1073/pnas.092562399
14. Lupton SD, Brunton LL, Kalberg VA, Overell RW (1991) Dominant positive and negative selection using a hygromycin phosphotransferase-thymidine kinase fusion gene. Mol Cell Biol 11(6):3374-3378
15. Murphy GJ, Mostoslavsky G, Kotton DN, Mulligan RC (2006) Exogenous control of mammalian gene expression via modulation of translational termination. Nat Med 12(9):1093-1099. doi: 10.1038/nm1376
16. Szentirmai O, Baker CH, Lin N, Szucs S, Takahashi M, Kiryu S et al (2006) Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: Correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect. Neurosurgery 58(2):365-372 (discussion-72)
17. Brocker T (2000) Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood 96(5):1999-2001
18. Pule MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK (2005) A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 12(5):933-941. doi: 10.1016/j.ymthe.2005.04.016
19. Gade TP, Hassen W, Santos E, Gunset G, Saudemont A, Gong MC et al (2005) Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res 65(19):9080-9088. doi: 10.1158/ 0008-5472.CAN-05-0436
20. Guest RD, Hawkins RE, Kirillova N, Cheadle EJ, Arnold J, O'Neill A et al (2005) The role of extracellular spacer regions in the optimal design of chimeric immune receptors: Evaluation of four different scFvs and antigens. J Immunother 28(3):203-211. doi: 10.1097/ 01.cji.0000161397.96582.59
21. Patel SD, Moskalenko M, Smith D, Maske B, Finer MH, McArthur JG (1999) Impact of chimeric immune receptor extracellular protein domains on T cell function. Gene Ther 6(3):412-419. doi: 10.1038/sj.gt.3300831
22. Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N et al (2006) CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 66(22):10995-11004. doi: 10.1158/0008-5472.CAN-06-0160
23. Wang J, Jensen M, Lin Y, Sui X, Chen E, Lindgren CG et al (2007) Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther 18(8):712-725. doi: 10.1089/hum.2007.028
24. Loskog A, Giandomenico V, Rossig C, Pule M, Dotti G, Brenner MK (2006) Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 20(10):1819-1828. doi: 10.1038/sj.leu.2404366
25. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M (2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol 20(1):70-75. doi: 10.1038/ nbt0102-70
26. Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC (2004) Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 64(24):9160-9166. doi: 10.1158/0008-5472.CAN-04-0454
27. Wick W, Naumann U, Weller M (2006) Transforming growth factor-beta: A molecular target for the future therapy of glioblastoma. Curr Pharm Des 12(3):341-349. doi: 10.2174/138161206775201901
28. Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE et al (2006) Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 66(6):3294-3302. doi: 10.1158/0008-5472.CAN-05-3773
29. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Bigner DD (2008) Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol 20(5):267-275. doi: 10.1016/ j.smim.2008.04.001
30. Jiang HR, Gilham DE, Mulryan K, Kirillova N, Hawkins RE, Stern PL (2006) Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors. J Immunol 177(7):4288-4298